1. Home
  2. MEG vs ABUS Comparison

MEG vs ABUS Comparison

Compare MEG & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Montrose Environmental Group Inc.

MEG

Montrose Environmental Group Inc.

HOLD

Current Price

$22.14

Market Cap

930.8M

ML Signal

HOLD

Logo Arbutus Biopharma Corporation

ABUS

Arbutus Biopharma Corporation

HOLD

Current Price

$4.19

Market Cap

848.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MEG
ABUS
Founded
2012
2005
Country
United States
United States
Employees
3500
19
Industry
Professional Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
930.8M
848.8M
IPO Year
2020
2008

Fundamental Metrics

Financial Performance
Metric
MEG
ABUS
Price
$22.14
$4.19
Analyst Decision
Buy
Strong Buy
Analyst Count
4
1
Target Price
$35.25
$5.00
AVG Volume (30 Days)
219.6K
1.6M
Earning Date
05-05-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
93.69
55.26
EPS
N/A
0.87
Revenue
$830,538,000.00
$14,083,000.00
Revenue This Year
$5.41
N/A
Revenue Next Year
$7.19
$239.71
P/E Ratio
N/A
$4.87
Revenue Growth
19.26
128.21
52 Week Low
$19.04
$3.04
52 Week High
$32.00
$5.10

Technical Indicators

Market Signals
Indicator
MEG
ABUS
Relative Strength Index (RSI) 52.09 41.74
Support Level $20.80 $3.68
Resistance Level $23.48 $4.62
Average True Range (ATR) 0.79 0.15
MACD 0.13 -0.01
Stochastic Oscillator 88.92 30.19

Price Performance

Historical Comparison
MEG
ABUS

About MEG Montrose Environmental Group Inc.

Montrose Environmental Group Inc is an environmental services company. The firm's operating segments are Assessment, Permitting and Response, Measurement and Analysis, and Remediation and Reuse. Through its Assessment, Permitting, and Response segment, the company provides scientific advisory and consulting services to support environmental assessments, environmental emergency response, and environmental audits and permits. Measurement and Analysis include test and analysis of air, water, and soil to determine concentrations of contaminants whereas, the Remediation and Reuse segment provide clients with engineering, design, implementation, operations and maintenance services, to treat contaminated water, and soil remediation. The company derives maximum revenue from United States.

About ABUS Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

Share on Social Networks: